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1123-187 Soluble CD40 Ligand in Pulmonary Arterial 
Hypertension: Possible Pathogenic Role of Interaction 
Between Platelets and Endothelial Cells
Jan K. Damås, Kari Otterdal, Arne Yndestad, Halfdan Aass, Nils Olav Solum, Stig S. 
Frøland, Svein Simonsen, Pål Aukrust, Arne K. Andreassen, Research Institute for 
Internal Medicine, Rikshospitalet, Oslo, Norway, Rikshospitalet, Oslo, Norway
Background: Inflammatory processes seem to be involved in the development and pro-
gression of pulmonary arterial hypertension (PAH). CD40 ligand (L) may induce various
biological responses such as matrix degradation and thrombus formation in several
inflammatory disorders. We hypothesized that CD40L also could be involved in the immu-
nopathogenic mechanisms of PAH.
Methods and Results: By comparing soluble (s) CD40L levels in 32 PAH patients and 8
controls, we found several significant differences: 1) Patients with primary pulmonary
hypertension (n=13) and secondary PAH (n=11) had increased sCD40L levels compar-
ing controls (p<0.05 and p<0.01, respectively). 2) In contrast, sCD40L levels were normal
in patients with chronic thromboembolic pulmonary hypertension (n=8) and in other PAH
patients using warfarin. 3) sCD40L levels were higher in arterial (femoral artery) compar-
ing mixed venous blood (pulmonary artery), suggesting production of CD40L in the pul-
monary vasculature. 4) Platelets from patients with PAH showed higher intracellular
levels, enhanced spontaneous and thrombin-stimulated release of sCD40L comparing
controls (p<0.01). Finally, in vitro studies demonstrated that sCD40L induced chemokine
expression (i.e. MCP-1 and IL-8) in endothelial cells. Indeed, MCP-1 and IL-8 were ele-
vated and correlated to pulmonary vasculature resistance in PAH (p<0.01). Surprisingly,
prostacycline enhanced MCP-1 levels in PAH patients in vivo and in CD40L-stimulated
HUVEC in vitro, suggesting some unfavorable effects of this medication in PAH.
Conclusion: Raised platelet-derived CD40L levels in PAH patients may (i) reflect
enhanced platelet activation and thrombus formation in these patients, and (ii) induce
chemokine expression in endothelial cells. These processes could contribute to the the
pathogenesis of this disorder.
1123-188 Role of Amlodipine in Preventing and Reversing 
Monocrotaline-Induced Pulmonary Arterial 
Hypertension in Rats
Eiichiro Mawatari, Minoru Hongo, Akio Sakai, Ruan Zonghai, Fumiaki Ogiwara, Noboru 
Watanabe, Yuichi Kamiyoshi, Osamu Kinoshita, Keishi Kubo, Shinshu University, 
Matsumoto, Nagano, Japan
Background: Amlodipine has been reported to be beneficial to improve coronary
microvascular endothelial function, inhibit proliferation of vascular smooth muscle cells
and expression of matrix metalloproteinase-1 in vascular endothelial cells, and exert anti-
oxidant actions. The present study was designed to examine the role of amlodipine in
preventing and reversing monocrotaline (MCT)-induced pulmonary arterial hypertension
(PAH) in rats. Methods: Rats were injected with 40 mg/kg of MCT subcutaneously and
randomized to either 6mg/kg/day of amlodipine in drinking water or placebo for 3 weeks.
Animals treated with MCT and survived for 3 weeks were assigned to either amlodipine
(6mg/kg/day) or placebo for next 3 weeks. The animals had measurement of cardiac
weights and pulmonary arterial pressure, and then underwent histologic and Western
blot analyses of the lung tissue after treatment. Results: Amlodipine immediately follow-
ing MCT injection markedly inhibited PAH (mean pulmonary arterial pressure: 32.0 ± 2.9
mmHg in the placebo group vs 16.4 ± 2.1 mmHg in the amlodipine-treated group, p <
0.01) with severe pulmonary vascular remodeling and right-sided heart failure. The sur-
vival rate at 3 weeks after treatment was significantly increased in the amlodipine-treated
group compared with the placebo group (90 % vs 44 %, p < 0.05). eNOS expression in
the lung tissue was significantly reduced in the placebo group, but it was markedly
improved after 3 weeks of amlodipine (p < 0.001). Late treatment with amlodipine did not
palliate PAH nor improved survival. Conclusions: Amlodipine immediately after MCT
injection inhibited development of PAH and improved survival in rats. These effects were
associated with marked upregulation of eNOS in the lung tissue. In contrast, amlodipine
failed to reverse established PAH. Thus, this study may provide an insight into therapeutic
strategy of amlodipine in PAH.
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1124-189 Degree of Physical Activity Is Associated With 
Subclinical Atherosclerosis in Patients Prone to 
Metabolic Syndrome
Milind Y. Desai, Khurram Nasir, Joel B. Braunstein, John A. Rumberger, Matthew J. 
Budoff, Wendy S. Post, Roger S. Blumenthal, Johns Hopkins University, Baltimore, MD
Background: Metabolic syndrome (MS) is a risk factor for the development of subclinical
atherosclerosis (SA). SA and lack of physical activity (PA) predict coronary heart disease,
however, it is not known whether duration and frequency of PA impacts development of
SA in patients prone to develop MS. We assessed the impact of different degrees of PA
on SA in patients with MS. Methods: We studied 779 patients with MS (patients with
overt diabetes were excluded) referred for electron beam tomography. MS was defined
as blood pressure > 130/85 mm Hg, triglycerides > 150 mg/dl, HDL < 40 mg/dl and body
mass index > 30 kg/m2 (subjects meeting > 2 criteria were included). Patients were
divided into 3 groups: 1 (n = 308) = no PA, 2 (n = 189) = PA < 30 minutes > 2 times/week
and 3 (n = 282)= PA > 30 minutes > 2-3 times/week. Abnormal coronary artery calcifica-
tion (ACAC) or significant SA was defined as a calcium score > 75th percentile based on
gender and age. Results: Patients were 67 % males with a mean age of 54 ± 9 years.
ACAC was present in 30 % of Group 1 patients, 28 % of Group 2 patients and 23 % of
Group 3 patients (figure). Patients without PA had 23 % higher relative probability of
ACAC than patients in the highest PA category (p < 0.05), a finding that persisted after
correction for gender. Lesser degree of PA did not significantly reduce the prevalence of
ACAC. Conclusion: Patients who are prone to MS have a higher prevalence of SA in the
presence of little or no PA relative to those who engage in PA at least 30 minutes per ses-
sions, 2 times a week.
1124-190 Inpatient Cardiac Risk Factor Management Program 
Can Promote Therapeutic Lifestyle Change
Joseph I. Miller, III, Michael Craig McDaniel, Laurence Sperling, The Starr Investigators, 
Deborah Wright, Emory Unversity School of Medicine, Atlanta, GA, Emory Heart Center, 
Atlanta, GA
Background: The STARR (Steps to Achieve Risk Reduction) program is a multi-disci-
plined inpatient program designed to improve patient knowledge of cardiac risk factors,
increase AHA/ACC guideline adherence, and promote lifestyle change. With shorter hos-
pitalizations, it is important to use systematic health delivery strategies for quality care.
While clinical goals have been obtained with similar programs, little is published regard-
ing the ability to promote longterm therapeutic lifestyle change (TLC) in the acute setting.
The STARR program addresses diet, exercise, weight loss, tobacco, stress, hyperten-
sion, lipids, and diabetes.
Methods: STARR utilizes a multi-disciplined approach to educate and manage cardiovas-
cular risk in patients admitted to Emory Hospital. The program uses an algorithm based
on clinical trials and AHA/ACC recommendations. Patient education is accomplished with
a multidisciplinary team and reinforced with educational booklets, magnets, stickers, and
patient contracts. Prior to STARR, a control group of 18 patients underwent phone inter-
view 5 months after discharge and answers recorded on a standardized database.
Patients were evaluated separately on their knowledge of risk reduction goals and self-
reported compliance with diet and exercise. Post STARR, 30 patients were followed 5
months after discharge to assess STARR's impact on knowledge and behavioral compli-
ance with risk reduction. Mean score differences were compared with unpaired Student's
t-test.
Results: Five months after discharge, the STARR patients’ knowledge of exercise and
diet goals was 56.7% (95%CI 47.2-66.1%) versus 18.2% (95%CI 9.5-26.9%) in controls
(p value <0.0001). The STARR patients’ exercise and diet compliance was 67% (95%CI
57.5-75.9) versus 43.5% (95% CI 33.2-53.8, p=0.002). In STARR patients, there was a
trend toward improvement in stress, weight, blood pressure, diabetic, and lipid goals.
Conclusion: An acute inpatient multi-disciplinary based program can influence knowl-
edge and compliance regarding TLC in diet and exercise. This benefit is sustained at 5
months and follow up will assess if it is maintained. Long term, STARR should lower car-
diac morbidity and mortality.
1124-191 Predictive Risk Factors for Coronary Events in Renal 
Transplant Patients
Hallvard Holdaas, Bengt Fellstroem, Alan Jardine, Ed Cole, Gudrun Nyberg, Carola 
Gronhagen-Riska, Soren Madsen, Hans-Hellmut Neumayer, Bart Maes, Patrice Ambuhl, 
Anders Olsson, Ingar Holme, Per Fauchald, Terje Pedersen, John Logan, The ALERT 
Study Group, University of Oslo, Oslo, Norway, Uppsala University, Uppsala, Sweden
A number of observational studies have indicated that coronary heart disease is more
common among renal transplant recipients than in the general population. However, in
renal transplant patients the relation between conventional cardiac risk factors and car-
diac events is less clear than in other populations. Renal transplant recipients may also
acquire non-traditional risk factors as a consequence of renal transplantation procedures.
In the ALERT study, 2102 stable renal transplant recipients (total cholesterol 4.0 – 9.0
mmol/l (received fluvastatin (n=1050) or placebo (n=1052) for a median period of 5.1
years. We analysed the role of traditional and non-traditional risk factors in the placebo
arm of the ALERT study (Lancet 2003;361:2024).
Methods. A univariate risk factor analysis to assess the influence of a large set of poten-
tial risk factors for a predefined composite endpoint (Cardiac Death or Non-fatal MI) was
performed. Subsequently a multivariate model building approach was used to determine
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a set of independent risk factors. The key findings, relative risks and 95% confidence
intervals were calculated and are presented below.
Results:
Conclusion. The data demonstrate that in renal transplant patients traditional risk factors
such as age, diabetes, previous coronary heart disease and lipid values are major deter-
minants of cardiac risk. The analysis also demonstrates that renal function and rejection
episodes are independent risk factors for cardiac events.
1124-192 Rosiglitazone Reduces Novel Biomarkers of 
Cardiovascular Disease in Subjects With Type 2 
Diabetes Mellitus Already on Statin Therapy
John D. Brunzell, Santica Marcovina, Dahong Yu, Alexander Cobitz, Errol Gould, Hongzi 
Chen, Lisa Porter, University of Washington, Seattle, WA, GlaxoSmithKline, King of 
Prussia, PA
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in type 2 dia-
betes (T2DM). Increased preponderance of small dense LDL particles and decreased
HDL are atherogenic factors associated with insulin resistance (IR) and the metabolic
syndrome. IR is also associated with hypercoagulable and proinflammatory states which
increase CVD risk. In T2DM, treatment with rosiglitazone (RSG) has demonstrated con-
version of the small dense LDL Type B phenotype (LDL Rf < 0.263) to the less athero-
genic Type A phenotype (LDL Rf > 0.263) as well as improvement in concentrations of
additional CVD biomarkers including CRP, PAI-1 and MMP-9. The effect of RSG on CVD
risks factors in T2DM subjects on statin therapy with predominately small dense LDL was
evaluated. Seventy two subjects on diet/exercise, or metformin monotherapy, who had
received at least 8 weeks of statin therapy, and had LDL Rf < 0.263 were randomized to
the addition of placebo (N=14) or RSG 4mg (N=29) or 8mg (N=29) TDD. Results: By
study end (Week 12), 24% (4mg) and 36% (8mg) of patients on RSG had converted to a
pattern of predominately large, buoyant LDL Rf (LDL Rf > 0.263) compared to no conver-
sion in the placebo group. Significant reductions in CRP and PAI-1 were observed in
RSG treated subjects. 
Conclusion: In T2DM subjects on statins, RSG significantly increased LDL particle size 
and reduced CRP and PAI-1, suggesting RSG may reduce CVD events.
1124-193 Dose of Fish Oil Needed to Achieve Cardioprotective 
Blood Levels of Omega-3 Fatty Acids
William S. Harris, Mid America Heart Institute, Kansas City, MO, University of Missouri-
Kansas City, Kansas City, MO
Background: The evidence for a cardioprotective effect of omega-3 fatty acids (FA) has
accumulated to the point where the American Heart Association (AHA) now recommends
that patients with known coronary heart disease (CHD) consume about 1 g/d of eicosap-
entaenoic and docosahexaenoic acids (EPA+DHA), and adults without disease should
eat at least two (preferably oily) fish meals per week. (The latter would provide about 500
mg/d EPA+DHA). Both epidemiological and interventional studies suggest that these
intakes will lower risk for death from CHD by 30%-50%. A variety of studies point to a red
blood cell (RBC) EPA+DHA level (hereafter, called the Omega-3 Index) of >=8% (percent
of total RBC FA) as a reasonable target value for cardioprotection. An Index of <=4% is
associated with relatively high risk. This study was undertaken to determine the effects of
AHA-recommended intakes of omega-3 FA from supplements on the Omega-3 Index.
Methods: Healthy subjects on stable background diets were randomized to supplementa-
tion with either 0 (placebo; n=22), 0.5 g (n=24), or 1.0 g (n=10) of EPA+DHA (ROPUFA-
30, Roche Vitamins). After five months, their Omega-3 Indexes were determined. Com-
pliance was determined by capsule count.
Results: Overall compliance was 95%, and it was not less than 75% for any subject. The
mean (SD) Omega-3 Indexes achieved were 4.3 (1.2%), 8.0 (1.7%), and 10.0 (2.8%),
respectively. Omega-3 Indexes of >=8% were achieved by 5%, 54%, and 80% of those
taking 0, 0.5g and 1.0 g/d, respectively. Indexes of <=4% were observed in 55%, 4% and
10% in each respective group.
Conclusions: These results suggest that most people taking 1 g EPA+DHA/d will achieve
or surpass the 8% target value for the Omega-3 Index, and that about half of those taking
500 mg/d will reach the 8% level. Thus, based upon blood levels likely achieved, AHA
recommended intakes should produce significant cardioprotection. The Omega-3 Index
identifies a risk factor that is easily, safely and inexpensively corrected and may represent
a novel, physiologically-relevant, independent and graded marker of risk for death from
CHD. (Sponsored in part by Roche Vitamins, Inc.).
1124-194 Metabolic Syndrome and Prevention of Premature 
Coronary Artery Disease
Ana Mari Schaper, Kwame Osei Akosah, Vicki Lynn McHugh, Sharon Ione Barnhart, 
Patricia A. Perlock, Troy Haider, Michelle Ann Mathiason, Gundersen Lutheran Health 
System, La Crosse, WI
Background: Metabolic Syndrome (MS) and primary prevention of coronary artery dis-
ease (CAD) is becoming increasingly appreciated. The National Cholesterol Education
Program (NCEP III) guidelines have defined MS and recommended aggressive manage-
ment. Consequently, an emphasis needs to be placed on the identification of persons
with MS. Lipoprotein subclass analysis allows for determination of atherogenic lipopro-
tein traits (ALT) of MS, but its incremental value remains unknown.
Objective: To determine the rate of MS in subjects screened for primary prevention and
to assess incremental value of ALT.
Methods: 254 young adults (women < age 65; men < 55) without known CAD, scheduled
for elective coronary angiogram had labs drawn for lipid and lipoprotein analysis (Lipo-
Science, Inc). MS per NCEP III was defined as the presence of >3 of the following traits:
low HDL (men <40 mg/dL; women <50 mg/dL), high triglyceride (> 150 mg/dL), hyperten-
sion (>130/85 mm Hg), fasting glucose (> 110 mg/dL), and BMI >30. ALT was defined as
>2 of the following values determined by nuclear magnetic resonance spectroscopy
(NMR): small LDL pattern B (< 20.5 nm), reduced large HDL (<11 mg/dL) and elevated
large VLDL (>27 mg/dL). CAD was defined as stenosis severity of > 50%
Results: Mean age was 53±8. 82% were overweight or obese. The mean total, LDL, and
HDL cholesterol levels were acceptable per NCEP III and not statistically different
between subjects with and without CAD. Mean triglyceride (170 versus 138 mg/dL,
p=0.002) and glucose (139 versus 109 mg/dL, p=0.005) were higher in those with CAD.
MS was present in 59 (24%) of participants. ALT was present in 85 (35%) of participants.
73 participants met criteria for CAD, of whom 26 (36%) had MS, and 35 (48%) had ALT.
The odds for MS in predicting CAD were 2.3 (CI: 1.3-4.2, p=0.006). The odds for ALT
were 2.2 (CI: 1.2-3.9, p=0.007). Using either criterion, as many as 43 (59%) of subjects
with CAD were identified (OR=2.6, CI: 1.5-4.5, p<0.001).
Conclusion: In a population of young adults with high levels of obesity and elevated trig-
lyceride, the use of both of these definitions provides incremental value in identifying
high-risk young adults who should be targeted for aggressive risk modification.
1124-195 Anthropomorphic Predictors of Insulin Sensitivity in a 
Healthy Population
Justo Sierra Johnson, Bruce D. Johnson, Kent R. Bailey, Stephen T. Turner, Mayo Clinic, 
Rochester, MN
Background: Insulin sensitivity (SI) is the capability of insulin to increase glucose dis-
posal. Abdominal fat distribution has been associated with insulin sensitivity. However, it
is not clear whether sophisticated measures (DEXA scanning) of body fat and fat distribu-
tion are better predictors of SI than simple measures (BMI, waist and hip circumferance,
waist-to-hip ratioWHR). Methods: We studied 256 healthy Caucasian subjects from
Rochester, MN (age 19-60, 133 women) who were admitted to the GCRC for measure-
ment of SI using the minimal model technique. All subjects had the simple and the
sophisticated measures of body fat distribution taken. Body fat measures were analyzed
and compared individually (controlling for age and gender) and in multiple regression
models, in relation to SI. Results: Among simple measures: waist circumferance and BMI
had the best correlations with SI (see Table), while the corresponding best predictors
among the DEXA measures were: head fat (raw and percent) and upper body fat. When
WHR and BMI were combined, or when head fat and upper body fat were combined, the
Risk factors at baseline (RR for) Univariate RR Multivariate RR
Age, years, 1 extra year 1.04 (1.02,1.05) 1.03 (1.01, 1.06)
Diabetes, Yes/No 2.35 (1.56, 2.35) 2.13 (1.32, 3.46)
Treatment for rejections, Yes/No 1.47 (1.00, 2.16) 1.5(1.01, 2.48)
Coronary heart disease, Yes/No 3.28 (2.08, 5.18) 2.11 (1.23, 3.62)
Total cholesterol, (1 extra mmol/L ) 1.31 (1.12, 1.55) 1.21 (0.97, 1.50)
LDL cholesterol (1 extra mmol/L ) 1.41 (1.18, 1.69) 1.34 (1.09, 1.66)
HDL Cholesterol (1extra mmol/L ) 0.55 (0.34, 0.90) 0.56 (0.31, 1.02)
Triglycerides (1extra mmol/L ) 1.11 (1.03, 1.19)
ST-T abnromalities, Yes/No 2.02 (1.32, 3.08)
Pulse Pressure (1 extra mmHg) 1.01 (1.00, 1.02)
Serum creatinine (10 extra umol/L) 1.05 (1.02, 1.08 1.05 (1.01, 1.09)
Aspirine use, Yes/No 1.65 (1.08, 2.54)
Placebo
N=14
RSG 4 mg
N=29
RSG 8 mg
N=29
% patients converted to
LDL Rf > 0.263 (%)
0 23.5 36*
Mean ∆ & %∆ (95% ci) from 
baseline:
LDL Rf -0.0003
(-0.0112, 0.0107)
0.011*
(0.0033, 0.0187)
0.014*
(0.0069, 0.0212)
CRP (%) 17.26
(-18.41, 68.50)
-35.38*
(-49.67, -17.05)
-39.08*
(-52.36, -22.10)
PAI-1 antigen (%) -22.69
(-42.12, 3.28)
-10.63
(-26.81, 9.13)
-22.65*
(-37.05, -4.96)
PAI-1 activity (%) -29.02
(-57.08, 17.38)
-17.30
(-41.45, 16.83)
-30.72*
(-51.14, -1.76)
MMP-9 (%) 20.13
(-14.59, 68.97)
-8.70
(-27.39, 14.79)
-17.76
(-34.44, 3.17)
* Statisticallysignificant
